
WilmerHale Advises Intercept Pharmaceuticals in \$460M Public Offering

JULY 18, 2016

Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, has announced the closing of an underwritten public offering of \$460 million aggregate principal amount of 3.25% convertible senior notes due 2023. Intercept used a portion of the proceeds from the offering to fund the payment of capped call option transactions for the purpose of reducing potential dilution in connection with the notes.

The WilmerHale team was led by Partner [Brian Johnson](#) and included Counsel [Chris Barnstable-Brown](#) and [Sarah Sellers](#) and Associate [Alicia Lee](#) on corporate and securities matters, Partners [Dino Wu](#) and [Jeannette Boot](#) on derivatives matters, Partner [John Sigel](#) on credit matters, and Partner [Julie Hogan Rodgers](#) and Counsel [Meghan Walsh](#) on tax matters.

Read [Intercept Pharmaceuticals' press release](#) for more information.